All News
Denosumab and Osteoporosis - A JAMA Review
An overview of denosumab use in osteoporosis (OP) by Bauer and Ensrud was published in JAMA.
Read Article
Rules on Mycophenolate Use in SLE
Dr. Diane Kamen. a rheumatologist and lupologist from the Medical University of South Carolina in Charleston, South Carolina, discusses the use of mychophenolate in the management of systemic lupus.
Read Article
JAK inhibitors reduce inflammation while potentially exacerbating the propagation viral infections. They suppress transcription of IFN-stimulated genes in non-infected cells (usually triggered by type I IFNs produced by infected cells) Thus facilitating viral propagation https://t.co/zOOTf7e1Hj
Dr. John Cush RheumNow ( View Tweet)
MMWR: 1994 the U.S. Vaccines for Children program has covered the cost of vaccines for US children. Since 1994 routine child vaccinations will have prevented ~508 million illness, 32 million hospitalizations, & 1,129,000 deaths,; direct savings of $540 billion & societal savings https://t.co/CBUojpR3Q8
Dr. John Cush RheumNow ( View Tweet)
Single center study of 1538 #SLE pts found 2.2% w/ lupus mesenteric vasculitis (LMV) - 39 LMV episodes in 31 pts - 2/3 had Nausea, vomiting, diarrhea & abdominal pain (~15% peritoneal irritation) & had active Dz (renal, Skin, Heme). LMV responded to steroids & https://t.co/vXCpbiC60P
Dr. John Cush RheumNow ( View Tweet)
Lupus Unlocked: Survey Responses
https://t.co/LQs7VKT6lq https://t.co/F7yqQvSvvZ
Dr. John Cush RheumNow ( View Tweet)
Lupus Unlocked: Pregnancy and SLE
In this webinar, panelists discussed issues such as congenital heart block, lupus nephritis treatment, teratogenic risks including conception on mycophenolate, antiphospholipid syndrome, hypertension management including the differential https://t.co/0RfAH7jW0J
Dr. John Cush RheumNow ( View Tweet)
Are PSO pts also Rx for PSA? Registry study of 17,310 PSO pts (19% also w PsA). @ baseline Biologics used in 44% of PSO, but higher rate in PSO+PsA (66% vs 39% PSO). 9.4% of PSO+PsA pts on Rx approved for PSO, but not explicitly for PsA. https://t.co/jMqk6gm1RR https://t.co/CQnwYO9yRO
Links:
Dr. John Cush RheumNow ( View Tweet)
Do SGLT2 and GLP-1 therapies have a role in Lupus?
Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP1-RA), initially developed to lower glucose in Type 2 Diabetes, also provide cardiovascular and renal protection for patients https://t.co/8JEfcv2BUz
Dr. John Cush RheumNow ( View Tweet)
Belimumab in SLE with Mucocutaneous or Vasculitis Findings
A post hoc analysis of a belimumab (BEL) inn systemic lupus erythematosus (SLE) study showed lupus mucocutaneous and vasculitic manifestations improve with BEL and standard care.
https://t.co/BlYWKLJPdb
Dr. John Cush RheumNow ( View Tweet)
Valves Gone Wild in SLE
Lupus valvulitis is a rare cardiac manifestation of active systemic lupus erythematosus (SLE) and is defined by inflammation of one or more cardiac valves. It is often associated with Libman-Sacks endocarditis (LSE), which is characterized by the https://t.co/XcC2POFDRd
Dr. John Cush RheumNow ( View Tweet)
2025 ACR Guideline for the Treatment of SLE
The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE.
https://t.co/2NFwTllLZa https://t.co/Q6smp1ZVH2
Dr. John Cush RheumNow ( View Tweet)
IMPACT Study - Certolizumab Efficacy in APS Pregnancies
A pilot trial assessed the safety and value of tumour necrosis factor α inhibitor treatment with certolizumab in patients with high-risk pregnancies with antiphospholipid syndrome (APS). Certolizumab (CZP) was shown to https://t.co/776CTvvGfb
Dr. John Cush RheumNow ( View Tweet)
Shifting the Management Paradigm for SLE and Lupus Nephritis
The paradigm for treating patients with systemic lupus erythematosus (SLE) is rapidly shifting and our patients will surely benefit with improved outcomes.
https://t.co/idxMBTyTwp https://t.co/f5G3cFb3XK
Dr. John Cush RheumNow ( View Tweet)
QUOTES TO LIVE BY: "it took me a long time be a good listener and be comfortable with silence. Its important to not just throwing facts back to patients who are suffering.
Sometimes pausing is powerful. Its all about establishing relationships " - Dr. Len Calabrese https://t.co/wcKX8nTa2o
Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine: Are Your Patients Taking It?
Dr. Nathalie Costedoat-Chalumeau dives into monitoring HCQ levels and what they tell us about patient adherence.
💡Learn how to spot non-compliance early.
👉 Now live on RheumNow: https://t.co/KPjyCrMTBr
#LupusCare https://t.co/vRASCc9kB0
Links:
Dr. John Cush RheumNow ( View Tweet)
Lupus QD Clinic - All Swells that Ends Well
Workup and management of SLE with periorbital edema, HA and seizures
Featuring Dr. Sheila Reyes, The Philippines
https://t.co/DrelXfe76Z https://t.co/dntYllhjWj
Dr. John Cush RheumNow ( View Tweet)
5 year cohort study showed that obese T2D (diabetes) pts, semaglutide significantly lowered risk of osteoporosis (HR 0. 61), & gout (HR 0. 63) vs sitagliptin. Semaglutided did not lower the risk of Knee (HR 1. 05) or hip osteoarthritis (HR 0. 88). https://t.co/MqMBKdsXlu https://t.co/VWIGIDhPMO
Dr. John Cush RheumNow ( View Tweet)
A retrospective VEXAS cohort study of 59 pts receiving 71 targeted Rx - 98%male, mean 71 yrs & 46% had myelodysplastic syndr. Treatments included tocilizumab(19), anakinra (13), azacitidine(13), baricitinib (11), & pred only (10). Best responses w/ azacitidine & tocilizumab https://t.co/jqDmKinPDt
Dr. John Cush RheumNow ( View Tweet)
Turkish study of 1263 primary care referrals to rheumatology found 35.7% with inflammatory rheumatic Dz (IRD), 17.7% osteoarthritis, and 11.2% regional pain syndromes. Another German study showed low risk of IRD if CRP <5 https://t.co/v5qYb7c7jP https://t.co/iq4NfcC3cH https://t.co/RQan6rQi8a
Links:
Dr. John Cush RheumNow ( View Tweet)
